NCT03659058View on ClinicalTrials.gov

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR

NACompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 1, 2018

Conditions

Fibrosis, Liver

Interventions

DRUG

silymarin

silymarin 140 three times daily

DRUG

Ursodeoxycholic Acid

Ursodeoxycholic Acid 500

DRUG

Antioxidants

Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg

DRUG

Colchicine

Colchicine 0.6

OTHER

FOLLOW UP

follow up by abdominal ultrasound and fibroscan every 6 month for 1 year

All Listed Sponsors

lead

Zagazig University

OTHER_GOV

NCT03659058 - Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR | Biotech Hunter | Biotech Hunter